Clinigen Group Plc (CLIN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

Clinigen Group Plc (CLIN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH420196D
  • |
  • Pages: 73
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Summary

Clinigen Group plc (Clinigen Group) is a pharmaceutical company that supplies medicines. The company offers specialty pharmaceuticals, which include cardioxane, ethyol, foscavir, savene and vibativ. It offers clinical trial services, IDIS managed access, global access and strategic services. Clinigen Group offers strategic services which include policy development, patient forecasting, market insight, program summary report, stakeholder engagement and real-world data services. The company's clinical trial services comprise direct-to-site delivery, demand-driven labelling and distribution, ancillary supply, investigator-initiated trial services, and technical consultancy services. It sells its products through a network of distributors in the UK and abroad. Clinigen Group is headquartered in Burton-on-Trent, the UK.

Clinigen Group Plc (CLIN)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Clinigen Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Clinigen Group Plc, Medical Devices Deals, 2011 to YTD 2017 11

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deal Details 14

Asset Purchase 14

Clinigen Acquires Rights to Totect from Biocodex USA 14

Clinigen Group Acquires Ethyol from AstraZeneca 14

Clinigen Acquires Savene, Oncology Support Therapy, From SpePharm 15

Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For USD33 Million 16

Partnerships 17

Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 17

Clinigen Enters into Agreement with Shionogi 18

Clinigen Enters into Distribution Agreement with Romark Labs 19

Clinigen Group Enters into Distribution Agreement with BioQ Pharma 19

Clinigen Group Partners with Horizon Pharma 20

Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 21

Cumberland Pharma Enters into Agreement with Clinigen 22

Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 22

Link Healthcare Enters Into Agreement With Sanochemia Pharmazeutika For Secrelux 23

EirGen Pharma Enters into Agreement with Equity Pharma 24

Licensing Agreements 25

Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 25

Clinigen Extends Licensing Agreement with Hospira for Foscavir 26

Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 27

Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 28

NobelPharma Enters Into Licensing Agreement With Clinigen For Foscavir 29

Clinigen Enters Into Licensing Agreement With Hospira For Foscavir 30

Link Healthcare Enters into Licensing Agreement with Salix Pharma for Relistor 31

Equity Offering 31

Clinigen Completes IPO For USD16 Million 31

Acquisition 33

Clinigen Group Acquires Link Healthcare for USD155.2 Million 33

Clinigen Group Acquires Idis Group for USD338 Million 34

Link Healthcare Acquires Equity Pharma Holdings, Pharma And Medical Technology Company 35

Clinigen Group Plc-Key Competitors 37

Key Employees 38

Locations And Subsidiaries 39

Head Office 39

Other Locations & Subsidiaries 39

Recent Developments 41

Financial Announcements 41

Mar 15, 2017: Clinigen Group: Strong H1 Performance with Adjusted EPS up 31% 41

Jan 25, 2017: Clinigen Group HY trading update: strong H1 performance with gross profit up 34% 48

Sep 28, 2016: Clinigen Group: Transformational Year Delivers 25% Growth In Adjusted EPS 50

Jul 20, 2016: Strong second half performance completes transformational year for Clinigen 59

Mar 02, 2016: Clinigen Group Announces Continued Strong Growth With Eps Up 21% 61

Mar 02, 2016: Continued Strong Growth With EPS Up 21% 67

Jan 19, 2016: Clinigen Group announces Half year trading update-2016 68

Corporate Communications 69

Sep 28, 2016: Shaun Chilton to take over as Chief Executive Officer 69

Other Significant Developments 70

Jul 18, 2017: Clinigen Group: Year End Trading Update 70

Mar 30, 2016: Clinigen Group has become a full member of the European Alliance for Access to Safe Medicines and Alliance for Safe Online Pharmacy in the EU 72

Appendix 73

Methodology 73

About GlobalData 73

Contact Us 73

Disclaimer 73

List of Figures

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 7

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9

Clinigen Group Plc, Medical Devices Deals, 2011 to YTD 2017 11

List of Tables

Clinigen Group Plc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6

Clinigen Group Plc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8

Clinigen Group Plc, Deals By Therapy Area, 2011 to YTD 2017 9

Clinigen Group Plc, Medical Devices Deals, 2011 to YTD 2017 11

Clinigen Group Plc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 12

Clinigen Acquires Rights to Totect from Biocodex USA 14

Clinigen Group Acquires Ethyol from AstraZeneca 14

Clinigen Acquires Savene, Oncology Support Therapy, From SpePharm 15

Clinigen Acquires Cardioxane, Oncology Support Therapy, From Novartis For USD33 Million 16

Clinigen Enters into Distribution Agreement with Mitsubishi Tanabe Pharma 17

Clinigen Enters into Agreement with Shionogi 18

Clinigen Enters into Distribution Agreement with Romark Labs 19

Clinigen Group Enters into Distribution Agreement with BioQ Pharma 19

Clinigen Group Partners with Horizon Pharma 20

Cumberland Pharma Enters into Marketing Agreement with Clinigen for Ethyol 21

Cumberland Pharma Enters into Agreement with Clinigen 22

Link Healthcare Enters Co-Marketing Agreement with Sigma-Tau 22

Link Healthcare Enters Into Agreement With Sanochemia Pharmazeutika For Secrelux 23

EirGen Pharma Enters into Agreement with Equity Pharma 24

Cumberland Pharma Enters into Licensing Agreement with Clinigen Group 25

Clinigen Extends Licensing Agreement with Hospira for Foscavir 26

Clinigen Enters Into Licensing Agreement With Theravance For Vibativ 27

Clinigen Enters Into Licensing Agreement With BL&H For Foscavir 28

NobelPharma Enters Into Licensing Agreement With Clinigen For Foscavir 29

Clinigen Enters Into Licensing Agreement With Hospira For Foscavir 30

Link Healthcare Enters into Licensing Agreement with Salix Pharma for Relistor 31

Clinigen Completes IPO For USD16 Million 31

Clinigen Group Acquires Link Healthcare for USD155.2 Million 33

Clinigen Group Acquires Idis Group for USD338 Million 34

Link Healthcare Acquires Equity Pharma Holdings, Pharma And Medical Technology Company 35

Clinigen Group Plc, Key Competitors 37

Clinigen Group Plc, Key Employees 38

Clinigen Group Plc, Other Locations 39

Clinigen Group Plc, Subsidiaries 39

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Clinigen Group Plc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

select a license

Single User License
USD 250 INR 16088
Site License
USD 500 INR 32175
Corporate User License
USD 750 INR 48263

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com